High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancer
- PMID: 2970218
- DOI: 10.1097/00000421-198808000-00003
High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancer
Abstract
Forty women with metastatic breast cancer were randomized to receive either mitomycin-C (MMC) (21 patients) or vindesine (19 patients) with high dose medroxyprogesterone acetate (MPA). Response rates were not significantly different (33% for MPA and MMC and 28% for MPA and vindesine); the duration of response was better for patients receiving the MMC combination (median of 10.5 months versus 6 months for those on the vindesine combination).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical